JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
125.22 USD
-0.94 (-0.75%)
125.22 USD
0 (0%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
JAZZ had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
Each year in the past 5 years JAZZ had a positive operating cash flow.
1.2 Ratios
JAZZ has a Return On Assets of -3.70%. This is in the better half of the industry: JAZZ outperforms 73.98% of its industry peers.
JAZZ has a Return On Equity of -10.92%. This is in the better half of the industry: JAZZ outperforms 73.98% of its industry peers.
JAZZ has a Return On Invested Capital of 5.47%. This is amongst the best in the industry. JAZZ outperforms 82.65% of its industry peers.
The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 15.28%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(5.47%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROIC | 5.47% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
The Operating Margin of JAZZ (15.03%) is better than 85.71% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
The Gross Margin of JAZZ (88.71%) is better than 92.35% of its industry peers.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
JAZZ has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, JAZZ has more shares outstanding
Compared to 1 year ago, JAZZ has a worse debt to assets ratio.
2.2 Solvency
JAZZ has an Altman-Z score of 1.36. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
JAZZ has a Altman-Z score of 1.36. This is in the better half of the industry: JAZZ outperforms 62.24% of its industry peers.
JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
JAZZ has a Debt to FCF ratio of 4.33. This is amongst the best in the industry. JAZZ outperforms 85.71% of its industry peers.
JAZZ has a Debt/Equity ratio of 1.17. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.17, JAZZ is doing worse than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.36 |
ROIC/WACC0.81
WACC6.76%
2.3 Liquidity
JAZZ has a Current Ratio of 1.62. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
JAZZ's Current ratio of 1.62 is on the low side compared to the rest of the industry. JAZZ is outperformed by 65.31% of its industry peers.
JAZZ has a Quick Ratio of 1.37. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.37, JAZZ is not doing good in the industry: 64.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -62.78% in the last year.
JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
The Revenue has been growing slightly by 4.52% in the past year.
The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
3.2 Future
JAZZ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.88% yearly.
JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.33% yearly.
EPS Next Y-74.75%
EPS Next 2Y1.92%
EPS Next 3Y4.78%
EPS Next 5Y6.88%
Revenue Next Year4.32%
Revenue Next 2Y5.24%
Revenue Next 3Y5.83%
Revenue Next 5Y6.33%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.86, which indicates a rather expensive current valuation of JAZZ.
83.16% of the companies in the same industry are more expensive than JAZZ, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.27, JAZZ is valued a bit cheaper.
A Price/Forward Earnings ratio of 5.69 indicates a rather cheap valuation of JAZZ.
JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 95.92% of the companies in the same industry.
JAZZ's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.86 | ||
| Fwd PE | 5.69 |
4.2 Price Multiples
90.31% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 95.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.13 | ||
| EV/EBITDA | 8.45 |
4.3 Compensation for Growth
The decent profitability rating of JAZZ may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.45
EPS Next 2Y1.92%
EPS Next 3Y4.78%
5. Dividend
5.1 Amount
No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
125.22
-0.94 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners102.03%
Inst Owner Change3.14%
Ins Owners2.44%
Ins Owner Change0.97%
Market Cap7.60B
Analysts84.8
Price Target190.45 (52.09%)
Short Float %9.57%
Short Ratio7.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.5%
Min EPS beat(2)-64.64%
Max EPS beat(2)-6.35%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-64.64%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-9.87%
EPS beat(12)4
Avg EPS beat(12)-16.71%
EPS beat(16)7
Avg EPS beat(16)-10.46%
Revenue beat(2)0
Avg Revenue beat(2)-6.37%
Min Revenue beat(2)-10.66%
Max Revenue beat(2)-2.09%
Revenue beat(4)1
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.73%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)3
Avg Revenue beat(16)-2.09%
PT rev (1m)0.35%
PT rev (3m)0.86%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)-2.25%
EPS NY rev (1m)10.13%
EPS NY rev (3m)4.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-0.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.86 | ||
| Fwd PE | 5.69 | ||
| P/S | 1.86 | ||
| P/FCF | 6.13 | ||
| P/OCF | 5.77 | ||
| P/B | 2.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.45 |
EPS(TTM)6.64
EY5.3%
EPS(NY)22.01
Fwd EY17.58%
FCF(TTM)20.44
FCFY16.33%
OCF(TTM)21.69
OCFY17.32%
SpS67.37
BVpS61.1
TBVpS-47.92
PEG (NY)N/A
PEG (5Y)3.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROCE | 6.92% | ||
| ROIC | 5.47% | ||
| ROICexc | 6.73% | ||
| ROICexgc | 82.21% | ||
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% | ||
| FCFM | 30.34% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexcg growth 3Y32.25%
ROICexcg growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.37 | ||
| Cap/Depr | 11.29% | ||
| Cap/Sales | 1.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.28% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 1.36 |
F-Score5
WACC6.76%
ROIC/WACC0.81
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
EPS Next Y-74.75%
EPS Next 2Y1.92%
EPS Next 3Y4.78%
EPS Next 5Y6.88%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
Revenue Next Year4.32%
Revenue Next 2Y5.24%
Revenue Next 3Y5.83%
Revenue Next 5Y6.33%
EBIT growth 1Y-0.29%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-55.43%
EBIT Next 3Y5.37%
EBIT Next 5Y7.57%
FCF growth 1Y25.59%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y-4.47%
OCF growth 3Y21.49%
OCF growth 5Y12.45%